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Abstract. Colorectal cancer is an endemic disease in the
Western world. Search for molecular signatures present
in primary tumors that predict tumor metastasis potential
has been proposed and in particular, a 17-gene molecular
signature is associated with poor survival in breast cancer,
prostate cancer, meduloblastoma and lymphoma in a recent
study. Using quantitative real-time PCR assay (qPCR), our
study observed tumor-normal differential RNA expression
in 15 of these 17 genes in a cohort of 52 stage III colorectal
cancer patients (all P<0.05), which signified the importance
of these 17 signature genes in colorectal cancer. Although no
significant correlation was found between tumor RNA levels
of these 17 genes and some of clinical features (age, gender,
and location, all P>0.05), two distinct groups among these
genes were observed with Spearman correlation scores >0.6
(P<0.01), suggesting co-expression/interaction within these
genes. Of the 37 patients for whom complete follow-up
data was available, 12 patients had recurrence and 25 had
no recurrence. There was no significant difference in tumor
RNA levels between recurrence and non-recurrence groups
for the 17 genes (all P>0.05), but the recurrence group had
more patients with mucinous tumors (9/12 vs. 7/25, P<0.05)
and more lymph node involvement (median 7.2 vs. 2.5,
P<0.05) compared to the non-recurrence group. Moreover,
survival analysis revealed a significant difference in patient
overall survival time between low and high tumor RNA levels
for 1 of the 17 genes (PTTG1, P=0.024). Our qPCR validation
study confirms the importance of most 17-gene molecular
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signature genes with differential RNA expression and
suggests the relevance of PTTG1 for survival in colorectal
cancers.
Introduction
Colorectal cancer (CRC) is an endemic disease in the Western
world and it is the second most common cause of death for
both men and women in the United States (1). Even though
there are major advances in diagnosis and treatment of the
disease, the mortality remains almost unaltered in the last 20
years (2). Initial CRC treatment is surgical, where staging is
the determinant factor in prognosis and therapeutic decisions.
Approximately 50% of patients who have curative surgical
resection will die of a disease secondary to metastasis after
surgery, and 80% of those will have recurrence of the disease
detectable within 2 years (1-3).
The advancement of DNA manipulation techniques have
promoted a significant increase in the knowledge of molecular
mechanisms involved in the development and progression of
cancer. Genomic analyses have supplied new markers that
can definitely help in prognostic and therapeutic prediction
based on tumor biology at molecular level. However, several
promising colorectal cancer progression markers, such as
p53, K-Ras, and cytokeratins, have not shown uniform results
(4-7). Many of these studies were based on a small, nonconsecutive series of patients, and the patient selection was
different in many ways such as variation in treatment time,
different mutations of tumors, research methods, all making
comparisons more difficult.
The studies have begun to identify groups of genes,
the molecular signatures, whose alterations are associated
with tissue abnormalities or altered outcome (8,9). This has
allowed description of new sub-classifications of patients
based on genomic analysis, which is different from traditionally clinical-pathological analysis (10). Reports of
successful applications in hematological malignancies,
breast cancer (11,12), bladder cancer (13), malignant melanomas (14) have recently shown the significance of molecular
signatures in primary tumors as prognostic markers based
upon the characteristics of gene expression that can predict
malignant potential of the tumors. In the studies of CRC,
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some new genes in the carcinogenous process have been
described that can be used to determine new sub-classifications
for staging based on the genomic analyses, and such molecular approaches are much more promising than the clinicalpathological parameters alone (15). For instance, Wang and
colleagues using microarray technology have identified a 23gene signature that predicts recurrence in Dukes' B patients
with 78% overall accuracy (16). The same approach has been
utilized in the attempt of determining the differences of the
gene expression between the tumors and the normal colonic
tissue (17).
Metastasis is the main event that leads to death of a cancer
patient. The search for molecular signatures present in a
primary tumor that can identify the metastasis potential
of each tumor has been described with promising results.
Rasmaswamy has proposed a 17-gene molecular signature
for metastasis in solid tumors (18). By using microarray
technology in Rasmaswamy's study, primary adenocarcinomas from breast, prostate, lung, colon, uterus and ovary are
compared with the metastasis from these adenocarcinomas.
Through refining and gene clustering, a group of 17 genes
that showed the molecular signature of metastasis in primary
adenocarcinomas has been identified (Table I). The solid
tumors presenting with the molecular signature of metastasis
have a high tumor recurrence and consequently a worst clinical
outcome. This 17-gene signature has also demonstrated
association with survival rates in breast cancer, prostate
cancer, meduloblastoma, and lymphoma. This model of
molecular signature supports the hypothesis that primary
tumors are pre-configured to metastasize and that this
propensity can be detected in the primary tumor at the initial
diagnosis.
Using quantitative real-time PCR in our study, we have
analyzed these 17 genes in human colorectal cancer and
paired normal colon tissues in order to further assess the significance of this model of molecular signature in predicting
outcome of patients with colorectal cancer.
Materials and methods
Patients and samples. Tumor specimens and paired normal
colon tissues used in this study were from 52 stage III colorectal cancer patients [29 male/23 female; age range, 39-96
(median, 79)]. Samples were snap-frozen in liquid nitrogen
immediately after surgery and stored at -80˚C. None of the
patients had received preoperative radiation or chemotherapy.
Tumor classification and differential grade were evaluated in
all of the cases: 41 enteric adenocarcinoma, and 11 mucinous,
and 1 grade I, 38 grade II, 13 grade III. Twenty-eight tumors
were localized in the right colon, 18 in the left colon, and the
remaining 6 in the rectum. The complete data from recurrence
was collected in 37 patients, 25 had no recurrence (67.6%),
and 12 with recurrence (32.4%). All recurrences were proved
by biopsies or imaging studies, and were considered distant
metastasis. The range of follow-up was a median of 19.9
months with limited available data. Written informed consent
was obtained from all of the patients for the investigators to
bank tumor tissue and to perform genomic analysis. This study
was approved by the Washington University Human Subjects
Committee.

Table I. The primer sequences of the 17 genes studied in the 52 CRC patients.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene
Gene name
Accession no.
Forward primer
Reverse primer
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
SNRPF
Small nuclear ribonucleoprotein F
AI032612
TGTAGATGGCTACATGAACATGCA
CACCTCTGATATAAAGGACATTATTACACC
EIF4EL3
Elongation initiation factor 4E-like3
AF038957
ACTCACACCGACAGCATCAAAAT
GTAGCACGCCAACAGAACAACA
COL1A1
Type 1 collagen, ·1
Y15915
CACCTACAGCGTCACTGTCGAT
GGGAGGTCTTGGTGGTTTTGTA
J03464
ACCCAGAGTGGAGCAGTGGTT
GGATACAGGTTTCGCCAGTAGAGA
COL1A2
Type 1 collagen, ·2
RUNX1
Runt-related transcription factor 1
D43969
TTCTTTCTCCCTGGTACAAACGTAT
AGGGTTCTGGGATATTCTCTCATG
PTTG1
Securin
AA203476
GAGTGCCTCTCATGATCCTTGA
GCTTGAAGGAGACTGCAACAGAT
LMNB1
Lamin B1
L37747
GCTTGAAGAACACTTCTGAACAGGAT
CGTTTGCAGCCCAAATTGTAA
HNRPAB
Heterogeneous nuclear ribonucleoprotein A/B M65028
AGAAGTCTATCAGCAGCAGCAGTATG
CTGGCTCTTGCCGTAGTTTGTAC
D00654
CGACAGGCATCGTCCTGGAT
GGCAGGGCATAGCCTTCATAGAT
ACTG2
Actin, Á2
MYLK
Myosin light chain kinase
U48959
TGCTGCTAGATTTGACTGCAAGAT
CTCCCTGATTGACTGGTCATCTTT
MYH11
Myosin, heavy chain 11
AF001548
AGCTGGAGGAGCAGGTCGA
GCAGCAAGATTTCCTTCAGCTTCT
RBM5
RNA binding motif 5
AF091263
AGCGCAAGAAGCAGTTTGATG
GTTGCCAATGTTACTGTGGTCAAT
CNN1
Calponin 1
D17408
TTGAGAACACCAACCATACACAGG
GTTCACCTTGTTTCCTTTCGTCTTC
HLA-DPB1 MHC Class II, DPB1
M83664
ACCAGCCTGGATAGTCCTGTCAC
CCAGCTCCCGTCAATGTCTT
MT3
Metallothionein 3
S72043
GCAAATGCACCTCCTGCAA
ACAGTCCTTGGCACACTTCTCA
DHPS
Deoxyhypusine synthase
U79262
CCTGGCGCCCACATACTTG
ATTGGGCACCAGCAGGTTTC
NR4A1
Nuclear hormone receptor TR3
L13740
CAAAGCAGATCGTGAGGAGGAA
GTCCATGGTGGGCTTGATGA
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Genes studied. The 17 genes which are from the previous
study (18) were chosen to be studied (Table I). Primers of
these 17 genes were designed using the software Primer
Express 2.0 (ABI, Foster City, CA) and sequence information
for these primers was displayed in Table I. All primers were
tested, the optimal annealing temperature was determined
with gradient PCR for all 17 genes, and a single band at
the right position with relevant amplicon size was confirmed
with gel visualization. In addition, the dissociation curve
feature in the ABI 7900 system showed the specific amplification for all 17 genes with a single peak of the melting
temperature.
Quantitative real-time reverse transcription-PCR. Regions
of high tumor cellularity were selected for RNA extraction
(median 86.3%; range, 65-95%). Tissue total RNA was
isolated from the colon tumor or adjacent normal colon
mucosa with the TRIzol RNA isolation kit (Invitrogen,
Carlsbad, CA), and the quality of RNA (i.e. A260/280>1.8
and the clear RNA bands for 28S, 18S and 5S were seen) was
confirmed in the Siteman Cancer Center Tissue Procurement
Core. After reverse-transcription into cDNA using Superscript
II reverse transcriptase (Invitrogen), the RNAs of 17 genes
were determined by real-time qPCR, which was carried out
in a 10-μl reaction mix containing 2 μl of cDNA (10 ng/μl),
5 μl of 2X SYBR-Green universal qPCR master mix (ABI),
and 3 μl or primer mix (400 nM each forward and reverse
primers). All real-time qPCR assays were performed in
triplicate on an ABI PRIMSM 7900 Sequence Detector
System (ABI) with the following program: 50˚C for 2 min
to activate uracil N-glycosylase enzyme, and 40 cycles at
95˚C for 15 sec, 54 or 6˚C for 30 sec, and 72˚C for 30 sec.
The sequence detection program calculates a threshold cycle
number (CT) at which the reporter fluorescence generated
by cleavage of the probe is statistically greater than that
of the background signal.
Measurement of relative RNA expression level. In this study,
relative expression level was calculated using a modified
comparative CT method, which uses actual real-time qPCR
amplification efficiency instead of assuming all sets of gene
primer and probe have approximately equal efficiency (19).
The gene encoding amyloid B precursor protein was used
as an internal reference gene, because it had near identical
expression between colon tumor and normal tissues in previous
serial analysis of gene expression analysis and less than a
3-fold change between all tumor and normal sample pairs
in this study. The relative expression level of an individual
target gene was normalized to the reference gene and to
one of all 104 colon tumor and normal RNA samples that
was with the maximum CT value (i.e., the lowest expression
level, called calibrator sample or 1X sample) in any target
gene. A mathematical model was applied to determine the
normalized relative expression level of a target gene in the
individual sample, using the following formula:
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where E target is the real-time qPCR efficiency of target gene
transcript, and E reference is the real-time qPCR efficiency
of reference gene transcript (20). Therefore, relative RNA
expression level of a gene in this study is a relative number
based on the reference gene and the 1X sample.
Statistical analysis. Statistical analyses were performed with
the software STATISTICA (StatSoft, Inc., Tulsa, OK).
Significance of the difference of relative expression level
between paired tumor and normal samples was evaluated by
Wilcoxon matched-pairs test. The influence of gender, tumor
location, pathological variables was evaluated with MannWhitney or Kruskal-Wallis test. Correlation between variables
was observed with Spearman rank correlation. Survival
analysis was carried out with the SAS LIFETEST procedure
(Cary, NC). The significance level was set at P<0.05. P-values
from multiple tests were corrected with the Bonferroni test.
Results
RNA expression of the 17 genes in colorectal tumor and
normal tissues. Fifty-two samples from colorectal tumors
and normal tissues each were studied simultaneously. There
was a significant difference in RNA expression level between
tumor and normal tissues in 15 of the 17 genes analyzed
(P<0.05 all), and the RNA expression of the remaining 2
genes (DHPS and NR4A1) had no significant difference
between tumor and normal tissues (Fig. 1).
Ratio expression of the 17 genes between tumor and normal
samples. The 17 genes were classified according to the ratio
of RNA expression between tumor and normal tissues; and
the tumor-normal ratio of the RNA expression was considered
up-regulated when the ratio was >1.2, and down-regulated
when <0.8. Of the 17 genes, 7 genes were classified as upregulated (SNRPF, EIF4EL3, COL1A1, COL1A2, PTTG1,
RUNX1, LMNB1; P<0.05), another 7 were down-regulated
(ACTG2, MYLK, MYH11, RBM5, CNN1, HLA-DPB1, MT3;
P<0.05), and the rest 3 genes statistically had no difference
in RNA expression between tumor and normal tissue as
shown in Table II.
Co-expression of the 17 metastasis genes. Correlations of the
RNA expression between all 17 genes were determined in 52
colorectal tumors. Statistically significant correlations were
demonstrated in 2 distinct gene-groups. The first group had 4
genes with up-regulated and 2 with normal RNA expression
(all Spearman coefficient >0.6, Table III). The other group
was formed with 10 genes, of which 7 were down-regulated,
2 up-regulated, and 1 had normal RNA expression (all
Spearman coefficient >0.6, Table III). The gene MT3 was
not shown to have any strong correlation with the other 16
genes. No evidence of such co-expression was observed in
the normal tissues.
Tumor RNA expression and patient clinical features. The
comparisons of the RNA expression were made with patient
age, gender, tumor location, histological type, pathological
grade, lymph node involvement, and recurrence at the last
follow-up. There was no statistically significant difference in
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Figure 1. Differential expression in relative RNA level of the 17 genes between tumor and matched normal mucosa tissues in 52 colorectal cancer patients.
(*P>0.05 for DHPS and NR4A1, P<0.05 in the rest 15 genes). Error bars represent 95% CI of the mean. All assay values were normalized to the internal
reference gene APP.

Table II. T/N category of the RNA expression in 52 CRC patients.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
No. of cases in category
No. of cases in category
No. of cases in category
Gene symbol
of T/N <0.8
of T/N = 0.8-1.2
of T/N >1.2
P-value
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Up-regulated
SNRPF
13
11
24
0.023
EIF4EL3
12
7
29
0.001
COL1A1
11
5
32
0.000
COL1A2
12
4
32
0.000
RUNX1
12
5
31
0.000
PTTG1
14
6
28
0.000
LMNB1
7
0
25
0.000
Down-regulated
ACTG2
MYLK
MYH11
RBM5
CNN1
HLA-DPB1
MT3

34
36
36
29
36
34
31

2
5
5
14
2
6
6

12
7
7
5
10
8
11

0.000
0.000
0.000
0.000
0.000
0.000
0.000

Normal
HNRPAB
22
11
15
0.134
DHPS
18
12
18
1.000
NR4A1
22
3
23
0.845
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

tumor RNA expression of these 17 genes across all different
clinical-pathological features when analyzed as a single
marker (all P>0.05). However, two groups of patients were
separated using the end point of clinical recurrence, and
37 patients of these two groups had complete clinical data

available for further analysis. Of the 37 patients, 12 patients
had recurrence and 25 had no recurrence. Although there
was statistically no significant difference in RNA expression
of the 17 genes between these 2 groups (P>0.05), but several
pathological features such as tumor histological type and
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The score is in bold if the P<0.001. The range of the higher scores is between 0.50 and 0.96.

Table III. Spearman rank correlation with RNA expression of the 17 genes in 52 CRC patients.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
SNRPF EIF4EL3 HNRPAB DHPS COL1A1 ACTG2 MYLK MYH11 RUNX1 NR4A1 RBM5 CNN1 HLADPB1 PTTG1 COL1A2 LMNB1
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
EIF4EL3
0.84
HNRPAB
0.79
0.62
DHPS
0.62
0.41
0.68
COL1A1
-0.19
-0.37
0.05
0.23
ACTG2
-0.06
-0.27
0.12
0.30
0.58
MYLK
0.01
-0.28
0.19
0.30
0.63
0.84
MYH11
-0.01
-0.29
0.19
0.28
0.64
0.84
0.80
RUNX1
0.17
0.02
0.31
0.50
0.65
0.46
0.56
0.55
NR4A1
-0.01
-0.19
0.14
0.43
0.55
0.49
0.42
0.41
0.55
RBM5
0.18
0.03
0.39
0.58
0.53
0.55
0.54
0.53
0.84
0.57
CNN1
-0.17
-0.40
0.08
0.29
0.68
0.87
0.81
0.82
0.41
0.57
0.43
HLADPB1
0.02
-0.09
0.25
0.45
0.59
0.52
0.61
0.61
0.51
0.49
0.53
0.63
PTTG1
0.85
0.85
0.67
0.43
-0.21
-0.15
-0.18
-0.19
0.01
-0.07
0.03
-0.26
-0.07
COL1A2
-0.16
-0.37
0.05
0.20
0.96
0.59
0.69
0.69
0.60
0.53
0.45
0.72
0.60
-0.20
LMNB1
0.60
0.63
0.52
0.30
-0.19
-0.28
-0.37
-0.38
-0.14
0.01
-0.10
-0.28
-0.28
0.74
-0.25
MT3
0.23
0.34
0.16
0.21
-0.08
0.01
0.02
0.01
0.14
0.12
0.13
-0.06
0.26
0.22
-0.09
0.09
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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lymph node involvement were statistically different between
the recurrence and non-recurrence groups (P=0.02 and 0.01,
respectively), i.e., the recurrence group had more patients
with mucinous tumor than the non-recurrence group (9/12
vs. 7/25, P<0.05) and there was a 7.2 vs. 2.5 of median lymph
node involvement for the recurrence and non-recurrence
groups (P<0.05), respectively. Moreover, survival analysis
revealed a significant difference in patient overall survival
time between low and high tumor RNA levels for 1 of the
17 genes (PTTG1, P=0.024) (Fig. 2).
Hierarchical clustering analysis in 52 colorectal tumors.
Clustering analysis with tumor RNA expression of the 17
genes was performed in the 52 patients with colorectal
cancer; and 3 distinct patient-groups were found (Fig. 3).
The tumor RNA expression was statistically significantly
different between these 3 groups (P<0.05) in majority of the
17 genes (14/17), but not in the other 3 genes (MT3, DPHS,
and HNRPAB). No significant difference was found for each
of the clinical-pathological features between these 3 patientgroups separated by clustering with tumor RNA expression
(P>0.05). These correlations were tested with patient age,
gender, tumor location, histological type, pathological grade,
differentiation, invasion, lymph node involvement, and status
of disease and recurrence. However, the hierarchical clustering
analysis had not shown these 3 to be distinct or any patientgroups in 52 normal tissues.
Discussion
The 17-gene signature that was previously related to poor
prognosis in different solid tumors (18) has been evaluated in
our study for the CRC stage III patients. Our study demonstrated that the RNA expression in CRC tumors is significantly different from matched normal mucosa, independent
of anatomic and clinical pathological variables in 15 out of
17 genes (P>0.05). These results might be a confirmation that
this group of genes can be involved in the development of
colorectal cancer, and probably in other solid tumors as well.
The differential expression between tumor and normal tissues
from CRC patients also suggests that these 17 genes may
have important role in tumor biology which favors tumor
classification and decision making for optimized therapy.
However, the RNA expressions of these 17 genes in the
tumors were not associated with disease recurrence or other
clinical-pathological features in our study and rather the tumor
type and lymph node involvement were shown to be useful
for prediction of disease recurrence in the pre-therapy setting.
These results did not establish a positive relationship between
the 17-gene molecular signature and tumor recurrence/
metastasis. Nonetheless, one of the 17 genes (PTTG1) has
been indicated a significant correlation with patient overall
survival, which is a potential survival biomarker although
more validation studies are needed. The difficulty to compare
studies of molecular analysis in literature is mainly due
to the techniques utilized and different selections of cancer
patients. The techniques utilized should be validated carefully
in such molecular analysis and results from such studies
should be interpreted with caution. Michiels and colleagues
(21) have re-analyzed the metadata from seven large studies
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Figure 2. Survival curve for 37 colorectal cancer patients with follow-up data. The analysis was performed with the Kaplan-Meier estimate model in the
SAS LIFETEST procedure.

Figure 3. Hierarchical clustering heat map for tumor RNA expression in 52 CRC patients. Columns represent tumor samples and rows represent the 17
genes. Red and green represent relative high and low RNA expression levels, respectively.

that have attempted to predict prognosis of cancer patients
on the basis of microarray analysis. The results from these
metadata suggest that the list of genes identified as predictors

of prognosis was highly inconsistent and molecular signatures
strongly depended on the selection of patients in the training
sets. For all but one study, the rate of misclassification
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decreased as the number of patients in the training set
increased. Five of the seven studies did not classify patients
better than chance. The conclusion is that the prognostic
value of published microarray results in cancer studies
should be considered with caution; and we advocate the
use of validation by repeated random sampling (22).
Although no correlations between the tumor gene
expression and clinical-pathological features were found in
our study, hierarchic clustering based on the RNA expression
in tumors has demonstrated the existence of 3 patient groups
and all clinical-pathological parameters among those 3
groups were not significantly different, suggesting that the
tumor RNA expression behaves in a different way on different
groups of patients with the same stage. This might explain
different biological behavior of tumors when classified
by clinical-pathological parameters, even for patients in
the same staging group. The characterization of molecular
signatures among these groups may allow the determination
of unique tumor biologic behaviors as well as different
clinical evolution in the same group of patients, who are
assigned into new different classifications on staging and
may need different treatment options for each specific
group.
Interactions between genes in a variety of cells are a
major challenge for understanding of gene functions in
complex cellular processes. How those genes work in a
certain organ and how they interact are a complex process,
which is the object of many studies. The big challenge will
be to unveil how this interaction occurs among different
genes biologically. In our study, there were two groups of
genes that are positively correlated with each other in the
RNA expression. The first group consisted of 10 genes and
the other group of 6 genes. The normal tissue RNA
expression of the 17 genes did not show such correlations in
the groups. These findings suggest that there are interactions
among those grouped genes, and require complementary
studies to determine how these interactions occur.
In conclusion, our qPCR validation study confirms the
importance of most 17-gene molecular signature genes
with differential RNA expression, and suggests the survival
relevance of PTTG1 in colorectal cancers. Additional studies
should be done to define the real place and function of these
17 genes in colorectal tumors, their relationship with tumor
metastasis, and the possible clinical applications.
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